



12-2009

# No Association of Obesity and Type 2 Diabetes Mellitus Related Genetic Variants With Colon Cancer

Cheryl L. Thompson  
*Case Western Reserve University*

Sarah J. Plummer  
*University of Southern California*


Thomas C. Tucker  
*University of Kentucky, thomas.tucker@uky.edu*

Graham Casey  
*University of Southern California*

Li Li  
*Case Western Reserve University*

**[Click here to let us know how access to this document benefits you.](#)**

Follow this and additional works at: [https://uknowledge.uky.edu/markey\\_facpub](https://uknowledge.uky.edu/markey_facpub)

 Part of the [Endocrinology, Diabetes, and Metabolism Commons](#), [Gastroenterology Commons](#), and the [Oncology Commons](#)

## Repository Citation

Thompson, Cheryl L.; Plummer, Sarah J.; Tucker, Thomas C.; Casey, Graham; and Li, Li, "No Association of Obesity and Type 2 Diabetes Mellitus Related Genetic Variants With Colon Cancer" (2009). *Markey Cancer Center Faculty Publications*. 76.  
[https://uknowledge.uky.edu/markey\\_facpub/76](https://uknowledge.uky.edu/markey_facpub/76)

This Article is brought to you for free and open access by the Cancer at UKnowledge. It has been accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [UKnowledge@lsv.uky.edu](mailto:UKnowledge@lsv.uky.edu).

---

**No Association of Obesity and Type 2 Diabetes Mellitus Related Genetic Variants With Colon Cancer**

**Notes/Citation Information**

Published in *Gastroenterology Research*, v. 2, no. 6, p. 311-316.

© The authors.

This is an open-access journal distributed under the terms of the [Creative Commons Attribution-NonCommercial 4.0 International License](#), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Digital Object Identifier (DOI)**

<https://doi.org/10.4021/gr2009.11.1323>

# No Association of Obesity and Type 2 Diabetes Mellitus Related Genetic Variants With Colon Cancer

Cheryl L. Thompson<sup>a, b, c</sup>, Sarah J. Plummer<sup>d</sup>, Thomas C. Tucker<sup>e</sup>, Graham Casey<sup>d</sup>, Li Li<sup>a, b, c, f</sup>

## Abstract

**Background:** Obesity and type 2 diabetes mellitus (T2D) are known risk factors for colon cancer. Recent reports from a number of genome wide association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs) associated with obesity and T2D. Here we tested the hypothesis that these SNPs may also be associated with risk of colon cancer.

**Methods:** We genotyped nine SNPs reported in GWAS of obesity and/or T2D, including SNPs in HHEX, KCNJ11, SLC30A8, FTO, CDKN2, CDKAL1, TCF2, and the rs9300039 SNP in an intergenic region, in 561 colon cancer cases and 721 population controls.

**Results:** None of these SNPs were statistically significantly associated with colon cancer in our sample.

**Conclusions:** Overall, these results suggest that these obesity and T2D genetic susceptibility loci are unlikely to influence the risk of colon cancer.

**Keywords:** Obesity; Type 2 diabetes; Colon cancer; Single nucleotide polymorphisms; Association

## Introduction

Obesity is now considered as a 'probable' cause for colon cancer [1], and insulin resistance with resulting metabolic perturbation is believed to be the key mechanism underlying the obesity-colon cancer link [2, 3]. Colon cancer and type 2 diabetes mellitus (T2D) share a remarkably similar risk factor profile, including obesity, high energy intake, a Western diet and physical inactivity. In addition, T2D itself is directly associated with colon cancer [2]. It is thus plausible that genetic susceptibility loci for obesity and T2D may also predispose to the development of colon cancer.

Genome-wide association studies (GWAS) have recently identified a number of novel single nucleotide polymorphisms (SNPs) that confer susceptibility to T2D [3-7] or obesity [8-11]. Although the functionality of these genetic variants is largely unknown, many of the genes in which the SNPs are located are known to be oncogenic or involved in molecular pathways implicated in carcinogenesis. For example, *HHEX* encodes a transcription factor in the homeobox family, and there is evidence that this gene can act as an oncogene [12]. *CDKN2* is a well known tumor suppressor gene [13] which stabilizes the tumor suppressor p53. Mutations of the *CDKN2* gene have been reported in numerous tumor types [14]. *TCF2* (*HNF1B*), like *HHEX*, encodes a homeobox transcription factor. *TCF2* has been recognized as a key player in carcinogenesis, especially in prostate cancer [15, 16].

To date, whether these genetic variants may also be associated with risk of cancer has not been investigated. We therefore tested this hypothesis in a population-based case-control study of colon cancer.

## Materials and Methods

### Study population

The study population is described elsewhere [17]. In brief, we recruited 561 incident colon cancer cases and 721 population controls. Colon cancer cases were identified via the

Manuscript accepted for publication November 18, 2009

<sup>a</sup>Departments of Family Medicine, Case Western Reserve University/University Hospitals of Cleveland, 10900 Euclid Ave, Cleveland, OH 44106, USA

<sup>b</sup>Epidemiology and Biostatistics, Case Western Reserve University/University Hospitals of Cleveland, 10900 Euclid Ave, Cleveland, OH 44106, USA

<sup>c</sup>The Case Center for Transdisciplinary Research on Energetics and Cancer, Case Comprehensive Cancer Center, 10900 Euclid Ave, Cleveland, OH 44106, USA

<sup>d</sup>Department of Preventive Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90089, USA

<sup>e</sup>Cancer Control Program, University of Kentucky, 2365 Harrodsburg Rd, Lexington, KY 40504, USA

<sup>f</sup>Corresponding author: Case Western Reserve University, 10900 Euclid Ave, UCRC II 306, Cleveland, OH 44106, USA. Email: li.li@case.edu

doi:10.4021/gr2009.11.1323

Kentucky Surveillance, Epidemiology and End Results (SEER) Cancer Registry within 6 months of diagnosis. Controls were recruited via random digit dialing. All individuals were asked to donate a sample of blood for genomic DNA. We used the National Cancer Institute Colon Risk Factor Questionnaire ([http://epi.grants.cancer.gov/documents/CFR/center\\_questionnaires/Colon/LA/ColonRiskFactor\\_USC.pdf](http://epi.grants.cancer.gov/documents/CFR/center_questionnaires/Colon/LA/ColonRiskFactor_USC.pdf)) to collect complete lifestyle and behavioral risk factors, including demographic variables, family history of colorectal cancer and non-steroidal anti-inflammatory drug (NSAID) use. Body mass index was calculated based on self-reported height and weight. The response rate was approximately 72% cases, and 63% for eligible controls. The study was approved by the institutional review boards of Case Western Reserve University/University Hospitals Case Medical Center, the University of Kentucky, Lexington, and the University of Southern California, Los Angeles.

### Selection of SNPs and genotyping

We selected nine SNPs previously identified to be associated with obesity (rs9939609 and rs8050136 in FTO) [8, 11] or T2D (rs1111875 in HHEX, rs5219 in KCNJ11, rs9300039, rs13266634 in SLC30A8, rs10811661 in CDKN2, rs7754840 in CDKAL1 and rs4430796 in TCF2) [3-7], as reported in GWAS through September 2007. All SNPs were genotyped by the TAQMAN assay using predesigned probe/primer sets from Applied Biosystems. Two percent of samples were repeated giving 100% concordance.

### Statistical analyses

We first tested the fit of each SNP to Hardy-Weinberg proportions using a Chi-square goodness of fit. Since cases were specifically ascertained to a disease we hypothesize would be associated with these SNPs, we only used controls in this analysis.

To examine the association of each SNP with colon cancer, we initially assessed the univariate (individual SNP) association via a chi-square test. We further obtained odds ratios (OR) via a logistic regression accounting for age, sex and race (base model) as well as after fully adjusting for age, sex, race, BMI, non-steroidal anti-inflammatory drug (NSAID) use, and family history of colorectal cancer (full model). In the logistic regressions, we tested three genetic models (dominant, recessive or additive). For the additive model, each individual was coded as 0, 1 or 2, representing the number of risk (less frequent) alleles they possessed for each SNP. Dominant models were coded as 1 if the individual possessed 1 or 2 copies of the risk allele, 0 otherwise, whereas the recessive models were coded as 1 only if the individual possessed two copies of the risk allele, and 0 otherwise. To address possible spurious associations resulting from population stratification, we also performed analyses

restricted to Caucasians only. SAS Version 9.1 (SAS Institute, Inc., Cary, North Carolina) was used to calculate all statistics. An  $\alpha = 0.05$  was used to declare statistical significance.

### Results

On average, cases were older and more likely to be male than controls (Table 1). Compared to controls, cases had a higher mean BMI ( $p = 0.0077$ ), were more likely to report a family history of colorectal cancer (24.0% vs. 15.4%,  $p = 0.0014$ ), more likely to be diagnosed with diabetes (20.9% vs. 15.6%,  $p = 0.019$ ), and less likely to regularly use NSAIDs ( $p = 0.16$ ).

All SNPs conformed to Hardy-Weinberg proportions among the controls ( $p > 0.05$ ). We found no statistically significant association for any of the SNPs in univariate analyses (Table 1). After adjustment for potential confounders, all associations remained non-significant (Table 2). When the analyses were restricted to Caucasians, we found very similar results. For brevity, we have only presented results from the entire sample here.

### Discussion

In this study, we found no association with colon cancer risk of a number of SNPs identified through T2D or obesity GWAS. Although many of the SNPs discovered through GWAS have been noted to have small effect sizes, we have at least 80% power to detect an odds ratio as low as 1.26, which is typical of most variants identified through GWAS, using the average minor allele frequency observed in these SNPs (33%) and assuming an additive model. Most of the SNPs included here are common variants with a relatively high frequency ( $> 10\%$ ) of the minor allele homozygotes. Thus it is unlikely that lack of statistical power could have obscured true association for these genetic variants. However, caution needs to be exercised for the KCNJ11 rs930039 and CDKN2 rs10811661 SNPs, for which the frequencies of the minor allele homozygotes are fairly low, limiting our power to detect an effect of these SNPs that truly follows a recessive mode of inheritance. Furthermore, we were able to replicate the association of the CDKAL1 rs7754840 SNP with self-reported T2D in this population, which compared to the most common GG genotype, individuals in our population with either the CG or CC genotype showed evidence of an increased risk of T2D ( $OR_{CG} = 1.53$ , 95% CI = 1.08-2.16;  $OR_{CC} = 1.63$ , 95% CI = 0.97-2.73;  $P_{dom} = 0.0095$  and  $P_{add} = 0.015$ ), lending credibility to our results.

There are limitations to our study. After we launched this project, other SNPs were identified in obesity or T2D GWAS, including *MCR4* [10], *TCF7L2* [3, 4] and *EXT2* [7],

**Table 1.** Descriptive Characteristics of Kentucky Colon Cancer Study Population

	Cases	Controls	p*
Gender – N (%)			< 0.001
Male	266 (47.3)	274 (38.0)	
Female	295 (52.7)	447 (61.0)	
Mean (stddev) age	62.8 (10.7)	58.3 (10.9)	< 0.001
Race – N (%)			0.24
African-American	27 (4.8)	23 (3.2)	
Caucasian	526 (93.8)	678 (94.0)	
Other	8 (1.4)	15 (2.1)	
Unknown	0 (0)	5 (0.7)	
Body Mass Index (kg/m <sup>2</sup> )	29.3 (6.1)	28.3 (6.2)	0.0077
Diabetes Diagnosis (%)**			0.019
Yes	105 (18.7)	105 (14.6)	
No	397 (70.8)	568 (78.8)	
Unknown	59 (10.5)	48 (6.7)	
Family History‡			0.0014
Yes	94 (16.8)	72 (10.0)	
No	297 (52.9)	395 (54.8)	
Unknown	170 (30.3)	254 (35.2)	
Regular NSAID Use <sup>†</sup>			0.16
Yes	235 (41.9)	306 (42.4)	
No	131 (23.4)	138 (19.1)	
Unknown	195 (38.8)	277 (38.4)	
HHEX – rs1111875			0.13
CC	217 (38.7)	241 (33.4)	
CT	255 (45.5)	348 (48.3)	
TT	88 (15.7)	131 (18.2)	
No call	1 (0.2)	1 (0.1)	
KCNJ11-rs5219			0.39
CC	226 (40.3)	304 (42.2)	
CT	265 (47.2)	316 (43.8)	
TT	68 (12.1)	100 (13.9)	
No call	2 (0.4)	1 (0.1)	
rs9300039			0.73
AA	9 (1.6)	8 (1.1)	
AC	103 (18.4)	136 (18.9)	
CC	448 (79.9)	576 (79.9)	
No call	1 (0.2)	1 (0.1)	
SLC30A8 – rs1326634			0.48
CC	274 (48.9)	329 (45.6)	
CT	230 (41.0)	319 (44.2)	
TT	55 (9.8)	71 (9.9)	
No call	2 (0.4)	2 (0.3)	
FTO-rs9939609			0.66
AA	90 (16.0)	121 (16.8)	
AT	252 (44.9)	336 (46.6)	
TT	217 (38.7)	261 (36.2)	
No call	2 (0.4)	3 (0.4)	
FTO-rs8050136			0.74
AA	91 (16.2)	119 (16.5)	
AC	250 (44.6)	336 (46.6)	
CC	217 (38.7)	265 (36.8)	
No call	3 (0.5)	1 (0.1)	
CDKN2 – rs10811661			0.34
CC	21 (3.7)	19 (2.6)	
CT	142 (25.3)	202 (28.0)	
TT	395 (70.4)	500 (69.4)	
No call	3 (0.5)	0 (0)	
CDKAL1 – rs7754840			0.75
GG	241 (43.0)	325 (45.1)	
CG	254 (45.3)	313 (43.4)	
CC	64 (11.4)	81 (11.2)	
No call	2 (0.4)	2 (0.3)	
TCF2 – rs4430796			0.81
AA	141 (25.1)	178 (24.7)	
AG	297 (52.9)	374 (51.9)	
GG	122 (21.7)	168 (23.3)	
No call	1 (0.2)	1 (0.1)	

\*Univariate (t-test or chi-square) p-value for association with colon cancer. For family history, type 2 diabetes diagnosis and NSAID use, this is a test of difference in positive vs. negative responses between cases and controls, ignoring unknown or missing data. \*\*Self-reported physician diagnosis of type 2 diabetes. †Regular non-steroidal anti-inflammatory drug (NSAID) use was defined as reporting ever use of NSAIDs at least twice a week for at least six months. ‡Family history of colorectal cancer

**Table 2.** Logistic Regression Association of SNPs With Colon Cancer

Gene	SNP	Base Model*		Full Model†	
		Case/Control	OR	p‡	OR
<b>HHEX</b>	<b>rs1111875</b>				
CC	217/241	1.0 (ref)	0.20	1.0 (ref)	0.22
CT	255/348	0.80 (0.62 - 1.03)		0.79 (0.60 - 1.03)	
TT	88/131	0.85 (0.60 - 1.19)		0.87 (0.61 - 1.24)	
TT vs. CC/CT		0.97 (0.52 - 3.10)	0.84	1.00 (0.72 - 1.37)	0.98
CT/TT vs. CC		0.81 (0.64 - 1.03)	0.089	0.81 (0.63 - 1.04)	0.097
<b>KCNJ11</b>	<b>rs5219</b>				
CC	226/304	1.0 (ref)	0.93	1.0 (ref)	0.32
CT	265/316	1.15 (0.90 - 1.47)		1.20 (0.92 - 1.56)	
TT	68/100	0.92 (0.63 - 1.32)		0.98 (0.67 - 1.56)	
TT vs. CC/CT		0.85 (0.60 - 1.20)	0.35	0.89 (0.62 - 1.27)	0.89
CT/TT vs. CC		1.10 (0.87 - 1.39)	0.44	1.15 (0.90 - 1.47)	0.28
<b>--</b>	<b>rs9300039</b>				
CC	448/576	1.0 (ref)	0.64	1.0 (ref)	0.85
AC	103/136	1.04 (0.78 - 1.41)		1.03 (0.75 - 1.41)	
AA	9/8	1.28 (0.48 - 3.45)		1.35 (0.46 - 3.95)	
AA vs. CC/CA		1.28 (0.47 - 3.47)	0.63	1.35 (0.46 - 3.92)	0.59
AC/AA vs. CC		1.06 (0.79 - 1.41)	0.71	1.05 (0.77 - 1.42)	0.77
<b>SLC30A8</b>	<b>rs13266634</b>				
CC	274/329	1.0 (ref)	0.60	1.0 (ref)	0.61
CT	230/319	0.92 (0.72 - 1.18)		0.88 (0.68 - 1.14)	
TT	55/71	0.94 (0.63 - 1.41)		0.99 (0.65 - 1.51)	
TT vs. CC/CT		0.98 (0.67 - 1.44)	0.94	1.05 (0.70 - 1.57)	0.81
CT/TT vs. CC		0.93 (0.74 - 1.17)	0.52	0.90 (0.71 - 1.15)	0.40
<b>FTO</b>	<b>rs9939609</b>				
TT	217/261	1.0 (ref)	0.35	1.0 (ref)	0.40
AT	252/336	0.90 (0.69 - 1.15)		0.84 (0.65 - 1.10)	
AA	90/121	0.86 (0.62 - 1.22)		0.84 (0.58 - 1.19)	
AA vs. TT/AT vs. AA		0.88 (0.70 - 1.12)	0.54	0.92 (0.66 - 1.27)	0.61
AT/AA vs. TT		0.92 (0.67 - 1.25)	0.32	0.84 (0.65 - 1.08)	0.17
<b>FTO</b>	<b>rs8050136</b>				
CC	217/261	1.0 (ref)	0.42	1.0 (ref)	0.48
AC	250/336	0.90 (0.70 - 1.16)		0.85 (0.65 - 1.11)	
AA	91/119	0.89 (0.64 - 1.25)		0.87 (0.61 - 1.11)	
AA vs. CC/AC		0.90 (0.71 - 1.14)	0.72	0.86 (0.67 - 1.83)	0.23
AC/AA vs. CC		0.95 (0.70 - 1.29)	0.37	0.95 (0.69 - 1.32)	0.76
<b>CDKN2</b>	<b>rs10811661</b>				
TT	395/500	1.0 (ref)	0.93	1.0 (ref)	0.086
CT	142/202	0.88 (0.68 - 1.15)		0.85 (0.65 - 1.12)	
CC	21/19	1.59 (0.83 - 3.03)		1.88 (0.93 - 3.81)	
CC vs. TT/CT		1.65 (0.86 - 3.16)	0.13	1.97 (0.98 - 3.97)	0.057
CT/CC vs. TT		0.94 (0.73 - 1.21)	0.63	0.93 (0.71-1.21)	0.56
<b>CDKAL1</b>	<b>rs7754840</b>				
GG	241/325	1.0 (ref)	0.35	1.0 (ref)	0.34
CG	254/313	1.15 (0.90 - 1.47)		1.21 (0.94 - 1.57)	
CC	64/81	1.11 (0.76 - 1.61)		1.16 (0.78 - 1.73)	
CC vs. GG/CG		1.04 (0.73 - 1.50)	0.87	1.05 (0.72 - 1.53)	0.80
CG/CC vs. GG		1.14 (0.91 - 1.44)	0.25	1.20 (0.94 - 1.53)	0.15
<b>TCF2</b>	<b>rs4430796</b>				
AA	141/178	1.0 (ref)	0.39	1.0 (ref)	0.74
AG	297/374	0.94 (0.71 - 1.25)		0.95 (0.71 - 1.28)	
GG	122/168	0.86 (0.62 - 1.20)		0.87 (0.61 - 1.24)	
GG vs. AA/AG		0.90 (0.68 - 1.18)	0.43	0.90 (0.67 - 1.20)	0.48
AG/GG vs. AA		0.92 (0.70 - 1.20)	0.53	0.92 (0.70 - 1.23)	0.60

\*Logistic regression controlling for age, sex and race (558 cases and 698 controls). †Logistic regression controlling for age, sex, race, family history of colorectal cancer, non-steroidal anti-inflammatory drug (NSAID) use and body mass index (BMI) (503 cases and 670 controls with complete data). ‡p-value of additive, dominant or recessive genetic model.



but were not included in our study. In addition, population stratification can bias genetic association studies and produce spurious findings [18], and we only crudely accounted for potential population stratification by adjusting for self-reported race. However, given our null findings, population stratification does not appear to be an issue in our sample. Our study sample represents the general population in Kentucky, which is predominantly Caucasian. The small number of participants other than Caucasians (< 6%) limits our ability to estimate effects in other races.

Furthermore, we did not adjust for multiple testing in this study, but instead, examined these SNPs as novel candidate variants and tested *a priori* hypothesis of the existence of an association with colon cancer. Further adjustment for multiple testing would not alter our conclusion of no association with any of these SNPs and colon cancer.

Overall, we do not find evidence of shared genetic risk factors for colon cancer with obesity or T2D. However, the strong epidemiological and biological evidence for common underlying mechanisms influencing T2D and cancer warrants further investigation.

## Grant Support

This research was supported by a Damon Runyon Cancer Research Foundation Clinical Investigator Award (CI-8), an R25 training grant from the National Cancer Institute (R25T CA094186), a K07 career development award from the National Cancer Institute (K07 CA136758-01A1), the Case Center for Transdisciplinary Research on Energetics and Cancer (1U54 CA-116867-01), and a National Cancer Institute K22 Award (1K22 CA120545-01).

## Financial Disclosures

None of the authors have any financial conflicts with this manuscript.

## References

1. Panel WCRFW. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Washington, DC: WCRF/American Institute of Cancer Research; 2007.
2. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. *Am J Clin Nutr* 2007;86(3):s836-842.
3. Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA, Dupuis J. Genome-wide association with diabetes-related traits in the Framingham Heart Study. *BMC Med Genet* 2007;8 Suppl 1(S16).
4. Salonen JT, Uimari P, Aalto JM, Pirskanen M, Kaikkonen J, Todorova B, Hypponen J, et al. Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium. *Am J Hum Genet* 2007;81(2):338-345.
5. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science* 2007;316(5829):1331-1336.
6. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 2007;316(5829):1341-1345.
7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 2007;445(7130):881-885.
8. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 2007;316(5826):889-894.
9. Liu YJ, Liu XG, Wang L, Dina C, Yan H, Liu JF, Levy S, et al. Genome-wide association scans identified CTN-NBL1 as a novel gene for obesity. *Hum Mol Genet* 2008;17(12):1803-1813.
10. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nat Genet* 2008;40(6):768-775.
11. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS Genet* 2007;3(7):e115.
12. George A, Morse HC, 3rd, Justice MJ. The homeobox gene Hex induces T-cell-derived lymphomas when over-expressed in hematopoietic precursor cells. *Oncogene* 2003;22(43):6764-6773.
13. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. *Exp Cell Res* 2001;264(1):42-55.
14. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. *Genes Chromosomes Cancer* 1996;15(2):77-88.
15. Frayling TM, Colhoun H, Florez JC. A genetic link between type 2 diabetes and prostate cancer. *Diabetologia* 2008;51(10):1757-1760.
16. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. *Biochim Biophys Acta* 1999;1424(2-3):M23-37.
17. Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G. Association between phosphatidylinositol 3-ki-

nase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. *Clin Cancer Res* 2008;14(3):633-637.

18. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. *Lancet* 2003;361(9357):598-604.